Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) is a Healthcare company (Biotechnology) with a market capitalization of $539M. The Maz Rating grades it against the other companies in its sector.
Ginkgo Bioworks Holdings, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $8.32, Ginkgo Bioworks Holdings, Inc. trades at 5.3x sales and 1.3x book value. Over the last twelve months it generated about $101M of revenue and a net loss of $274M. It runs a gross margin of 88.8%, an operating margin of -242.5% and a net margin of -249.2%. It shows return on equity of -56.9%, return on invested capital of -27.7% and a free cash flow yield of -34.6%. On the balance sheet: a debt-to-equity ratio of 1.01 and a current ratio of 4.72. Over the past 52 weeks the share price ranged from $5.37 to $18.22, with a beta of 1.75.
Ginkgo Bioworks Holdings, Inc. does not currently pay a dividend.
11 Wall Street analyst ratings cover the stock: 4 Buy, 3 Hold and 4 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Ginkgo Bioworks Holdings, Inc. (DNA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 50.3% / 30% · Interest income / Revenue 11.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 47.8% / 33% · Receivables / Mkt Cap (36m) 1.93% / 49% · Interest income / Revenue 11.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 47.8% / 33.33% · Receivables / Mkt Cap (24m) 1.93% / 33.33% · Interest income / Revenue 11.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 33.9% / 33.33% · Receivables / Avg Assets (4Q) 1.67% / 33.33% · Interest income / Revenue 11.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 30.2% / 33.33% · (Cash+Recv) / Total Assets 31.4% / 33.33% · Interest income / Revenue 11.0% / 5% | Fail |
No. As of September 2026, Ginkgo Bioworks Holdings, Inc. (DNA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Ginkgo Bioworks Holdings, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 11.0% of each dividend: Ginkgo Bioworks Holdings, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.